Search…

Lates News

20/08/2025

Every AI newsletter, Pacific Securities issued a research report on August 20th, giving a buy rating to the Puruo Pharmaceutical (000739.SZ). The rating reasons mainly include: 1) Q2 revenue and profit under pressure, gross margin significantly improved; 2) CDMO business gradually entering the harvest period, gross profit contribution exceeding API business for the first time; 3) share buybacks show long-term development confidence. (Daily Economic News)

Latest

3 m ago

Tonghua Jinma: Net profit for the first half of 2025 increased by 34.77% year-on-year.

3 m ago

According to a report released by Open Source Securities on August 20, each quick AI newsletter gives Jingrui Pharmaceuticals (600285.SH) a buy rating. The main reasons for this rating include: 1) Completion of external expansion mergers to promote the creation of a second growth curve; 2) Continuous strengthening of research and development innovation to enhance brand power. (Daily Economic News)

4 m ago

Baiyang Pharmaceuticals: Controlling shareholder to increase capital and expand shares, leading to proposed changes in ownership structure.

4 m ago

Da Sin Bank Group (02356.HK) announces its interim performance. Shareholders' attributable profit increased by 13.1% year-on-year to HK$1.579 billion.

4 m ago

Aero Energy: The company's technology and products do not involve AIDC

See all latest